Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy.
van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE, Slootbeek PHJ, Kroeze LI, Bruchertseifer F, Morgenstern A, Haberkorn U, Kratochwil C, Nagarajah J, Gerritsen WR. van der Doelen MJ, et al. Among authors: morgenstern a. Urol Oncol. 2021 Oct;39(10):729.e7-729.e16. doi: 10.1016/j.urolonc.2020.12.002. Epub 2021 Jan 11. Urol Oncol. 2021. PMID: 33353867 Free article.
213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe.
Seidl C, Port M, Gilbertz KP, Morgenstern A, Bruchertseifer F, Schwaiger M, Röper B, Senekowitsch-Schmidtke R, Abend M. Seidl C, et al. Among authors: morgenstern a. Mol Cancer Ther. 2007 Aug;6(8):2346-59. doi: 10.1158/1535-7163.MCT-07-0132. Mol Cancer Ther. 2007. PMID: 17699730
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R, Magdolen V, Seidl C. Knör S, et al. Among authors: morgenstern a. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64. doi: 10.1007/s00259-007-0582-3. Epub 2007 Sep 22. Eur J Nucl Med Mol Imaging. 2008. PMID: 17891393
Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells.
Bryan RA, Jiang Z, Huang X, Morgenstern A, Bruchertseifer F, Sellers R, Casadevall A, Dadachova E. Bryan RA, et al. Among authors: morgenstern a. Antimicrob Agents Chemother. 2009 Apr;53(4):1679-82. doi: 10.1128/AAC.01334-08. Epub 2009 Jan 12. Antimicrob Agents Chemother. 2009. PMID: 19139285 Free PMC article.
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.
Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Müller JM, Alke A, Seidl C, Bruchertseifer F, Morgenstern A, Senekowitsch-Schmidtke R, Essler M. Drecoll E, et al. Among authors: morgenstern a. PLoS One. 2009 May 27;4(5):e5715. doi: 10.1371/journal.pone.0005715. PLoS One. 2009. PMID: 19479088 Free PMC article.
285 results